PLA2R1 and nodular goiter: Figure 3 shows the ROC curve for the level of serum anti-PLA2R-IgG in controls and patients with HT, Graves' disease, nodular goiter, and IMN; the areas under the curve for the analysis of sensitivity for HT, Graves' disease, nodular goiter, and IMN were 1.000 ± 0.001, 0.569 ± 0.069, 0.402 ± 0.084, and 0.926 ± 0.027, respectively.